Jeffrey L Carroll

US Patent:

6890928, May 10, 2005

Filed:

Sep 5, 2003

Appl. No.:

10/657034

Inventors:

John N. Freskos - Clayton MO, US
Yvette M. Fobian - Wildwood MO, US
Thomas E. Barta - Evanston IL, US
Daniel P. Becker - Glenview IL, US
Louis J. Bedell - Mt. Prospect IL, US
Terri L. Boehm - Ballwin MO, US
Jeffrey N. Carroll - Columbia IL, US
Gary A. DeCrescenzo - St. Charles MO, US
Susan L. Hockerman - Chicago IL, US
Darren J. Kassab - Wildwood MO, US
Steve A. Kolodziej - Ballwin MO, US
Joseph McDonald - Wildwood MO, US
Deborah A. Mischke - Defiance MO, US
Monica B. Norton - St. Louis MO, US
Joseph G. Rico - Ballwin MO, US
John J. Talley - Boston MA, US
Clara I. Villamil - Glenview IL, US
Lijuan Jane Wang - Wildwood MO, US

Assignee:

Pharmacia Corporation - St. Louis MO

International Classification:

A61K031/445
A61K031/35
C07D401/02

US Classification:

514256, 514317, 514318, 514321, 514326, 514336, 514364, 514365, 514374, 514376, 514382, 514389, 514392, 514422, 514444, 549 60, 546194, 546197, 546207, 546209, 546210, 546211, 546213, 5462817, 5462821, 544335

Abstract:

This invention is directed to aromatic sulfone hydroxamic acids (including hydroxamates) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.